High serum uric acid trajectories are associated with risk of myocardial infarction and all-cause mortality in general Chinese population

Xue Tian1,2, Yingting Zuo1,2, Shuohua Chen3, Shouling Wu3*, Anxin Wang4,5* and Yanxia Luo1,2*

Abstract

Background: Long-term patterns of serum uric acid (SUA) and their association with the risk of myocardial infarction (MI) and mortality are poorly characterized as prior studies measured SUA at a single time point. This study aimed to identify SUA trajectories and determine their associations with incident MI and all-cause mortality.

Methods: We included 85,503 participants who were free of MI in or prior 2012 from the Kailuan study. SUA trajectories during 2006–2012 were identified by group-based trajectory modeling. Cox proportional hazard models were used to assess the association of SUA trajectories with MI and all-cause mortality.

Results: We identified three SUA trajectories during 2006–2012: low-stable (n=44,124, mean SUA: 236–249 μmol/L), moderate-stable (n=34,431, mean SUA: 324–354 μmol/L) and high-stable (n=6,984, mean SUA: 425–463 μmol/L). During a median follow-up of 6.8 years, we documented 817 (0.96%) incident MI and 6498 (7.60%) mortality. Compared with the low-stable group, high-stable group experienced a higher risk of MI (hazard ratio [HR], 1.35; 95% confidence [CI], 1.07–1.71) and all-cause mortality (HR, 1.22; 95% CI, 1.12–1.33). Multiple sensitivity analyses yielded similar results. Additionally, the association of SUA trajectory with MI and all-cause mortality was more pronounced in individuals without a history of hypertension (P-interaction=0.0359) and those aged <60 years (P-interaction<0.0001), respectively.

Conclusions: Higher SUA trajectories were associated with altered risk of MI and all-cause mortality, suggesting that monitoring SUA trajectory may assist in identifying subpopulations at higher risk of MI and all-cause mortality.

Keywords: Serum uric acid, Trajectories, Myocardial infarction, All-cause mortality

Introduction

Serum uric acid (SUA) is the end-product of purine metabolism via xanthine oxidoreductase in the human body and is mainly eliminated by the kidney and the intestinal tract [1]. SUA has been shown to have antioxidant and pro-inflammatory properties [2–4]; elevated SUA is associated with a wide variety of adverse health outcomes, such as hypertension [5], diabetes [6], and chronic kidney disease [7]. However, whether SUA is associated with higher risk of myocardial infarction...
(MI) and mortality has long been under debate [8–17]. Evidence from previous epidemiological studies yield inconsistent findings and was mainly limited by a single measurement of SUA. Thus, current evidence on the association of SUA with MI and mortality needs to be interpreted with caution, considering the wide heterogeneity in study designs and methodological limitations.

Since SUA changes over time, several previous studies focused on the effect of changes in SUA on the risk of cardiovascular disease and all-cause mortality, whereas the conclusions were controversial. However, changes in SUA in the aforementioned studies were defined on the basis of 2 measurements of SUA levels and were unable to account for the potential heterogeneity in changes in SUA levels. In addition, the study subjects were mainly patients with certain diseases, which further limits the generalizability of their results to the general population. To date, long-term patterns in SUA and their association with incident MI and all-cause mortality in the general population are still poorly characterized. Because high SUA is potentially one of the modifiable mediators of cardiovascular diseases and mortality, effective treatment and prevention interventions should have a profound favorable impact on public health [18].

Therefore, the aims of this study were to identify SUA trajectories over a 6-year exposure period and to examine the association between SUA trajectories and subsequent risk of MI and all-cause mortality in Chinese general population.

Methods
Study population
Data were obtained from the Kailuan study, which is a community-based prospective cohort study conducted in Tangshan, China. The details of the study design and procedures have been described previously [19–21]. Since June 2006 (the baseline survey), a total of 101,510 participants (81,110 men and 20,400 women, aged 18–98 years) were enrolled from 11 hospitals in the Kailuan community and underwent questionnaire assessments, clinical examinations, and laboratory tests. Then all participants were followed up every 2 years and incidence of chronic diseases (e.g. cardiovascular disease) was recorded annually. In the present study, SUA trajectories were developed from 2006 to 2012 to predict MI and all-cause mortality risk after 2012. Participants were excluded if they had MI or died in or prior 2012 or if they did not have at least 2 measurements of SUA during 2006–2012. Following these exclusions, we included 85,530 participants in the current analysis (Fig. 1). The baseline characteristics of included participants and excluded participants due to missing data on SUA are showed in Table S1.

Assessment of SUA
Fasting blood samples were collected in the morning after an 8- to 12-h overnight fast and transfused into vacuum tubes containing ethylene diamine tetra-acetic acid. The concentration of SUA was examined with a commercial kit (Ke Hua Biological Engineering Corporation, Shanghai, China) using an automatic biochemical analyzer (Hitachi 7600, Tokyo, Japan) according to the manufacturer’s instructions.

Assessment of outcomes
The primary outcomes of our study were incident MI and all-cause mortality. The database of MI diagnoses was obtained from the Municipal Social Insurance Institution.
and Hospital Discharge Register and was updated annually during the follow-up period. We used the International Classification of Disease, 10th Revision code for the identification of potential MI (I21). Diagnosis of MI was based on a combination of chest pain symptoms, electrocardiographic signs, and cardiac enzyme levels [22]. A panel of 3 cardiologists reviewed the medical records of potential MI cases to confirm diagnosis. All-cause mortality data were gathered from provincial vital statistics offices and reviewed by physicians.

Assessment of covariates
Demographic and clinical characteristics, including age, sex, education, income, smoking status, alcohol use, physical activity, and medical history, were collected via standardized questionnaires. Educational attainment was categorized as illiteracy or primary school, middle school, and high school or above. Income level was categorized as <800 yuan and ≥800 yuan. Smoking status was classified as never, former, or current. Alcohol consumption was calculated (in grams per day) via the frequency of intake (times per day) multiplied by the usual amount of alcoholic beverage consumed and the corresponding average ethanol content of that beverage (5.0g for 100 beer, 12.0g for 100 wine, 40.0g for hard liquor) [23, 24]. A standard drink (classified as “one severing” in the study) contained around 14.0g of ethanol.2 Based on the definition of one standard drink, we classified participants into the following categories of alcohol consumption: non-drinkers, light drinkers (women: 0–0.4 serving/day; men: 0–0.9 severing/day), moderate drinkers (women: 0.5–1.0 serving/day; men: 1.0–2.0 severing/day), and heavy drinkers (women: >1.0 serving/day; men: >2.0 severing/day) [25]. Active physical activity was defined as ≥80 minutes activity per week. Body mass index was calculated by dividing body weight (kg) by the square of height (m). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured 3 times with the participants in the seated position using a mercury sphygmomanometer, and the average of 3 readings was used in the analyses. All blood samples were tested using a Hitachi 747 auto-analyzer (Hitachi, Tokyo, Japan) at the central laboratory of the Kailuan Hospital. The biochemical indicators tests included fasting blood glucose (FBG), serum lipids, serum creatinine, and high sensitivity C-reactive protein (hs-CRP). Estimated glomerular filtration rate (eGFR) was calculated using the creatinine-based Chronic Kidney Disease Epidemiological Collaboration (CKD-EPI 2009) equation designed for White race [26].

Hypertension was defined as any self-reported hypertension or use of antihypertensive drug, or blood pressure ≥140/90 mm Hg. Diabetes mellitus was defined as any self-reported diabetes mellitus or use of glucose-lowering drugs, or FBG ≥7 mmol/L. Dyslipidemia was defined as any self-reported history or use of lipid-lowering drugs, or serum total cholesterol (TC) ≥5.17 mmol/L. Metabolic syndrome was defined according to updated ATP-III criteria [27].

Statistical analyses
SUA trajectories were identified by group-based trajectory modeling using SAS PROC TRAJ [28]. This method can automatically divide the study population into classes, in such a way that participants in the same class tend to have similar trajectories of SUA change. We used a censored normal model appropriate for continuous outcomes. Model fit was assessed using the Bayesian information criterion (BIC). Initially, all SUA trajectories started with quadratic shapes and compared the BIC with the models of two, three, four and five classes. The results showed that the optimal number of trajectories was three. Next, we compared the model with different functional forms. Cubic, quadratic, and linear terms were considered and evaluated based on their significance level, starting with the highest polynomial. In our final model, we had one pattern with a linear order term and two patterns with up to quadratic order terms (Fig. 2).

Baseline characteristics were described as mean ± standard deviation (SD) for continuous variables and percentages for categorical variables. Difference in means and proportions between groups was compared using Student’s t-test, ANOVA, or chi-squared test, as appropriate. Person–years was computed from the date of the 2012 survey to the date of MI diagnosis, mortality, or the end of the follow-up (December 31, 2019), whichever came first. The MI and all-cause mortality probabilities were estimated by Kaplan–Meier method and compared by log–rank test.

Cox proportional hazard regression was used to examine the association between SUA trajectories from 2006 to 2012 and the risk of MI and all-cause mortality by calculating hazard ratios (HRs) and 95% confidence intervals (CIs). The models met the proportional assumption criteria according to Schoenfeld residuals and log-log inspection. Three models were constructed. Model 1 was unadjusted. Because age and sex are strong determinants of exposure and outcomes, these factors was adjusted in Model 2. We further adjusted for education, income, smoking status, drinking status, physical activity, history of hypertension, diabetes and dyslipidemia, use of anti-hypertensive agents, hypoglycemic agents, lipid-lowering agents, BMI, SBP, DBP, FBG, TC, eGFR, hs-CRP at baseline, and baseline SUA in model 3.

Sensitivity analyses were performed to test the robustness of our findings. First, to control the
regression-to-then mean influence, we adjusted average BMI, SBP, DBP, FBG, eGFR, hs-CRP, and SUA during the exposure period. Second, to reduce the possibility of reverse causality, we conducted a lag-analysis by excluding incident MI or death, separately, with onset during the first 2 years of follow-up. Third, we adjusted for metabolic syndrome instead of its components. Fourth, we used the Fine-Gray competing risk model considering non-MI deaths as competing risk events to assess the association between SUA trajectory and MI. Fifth, we excluded participants with cardiovascular or cerebrovascular disease at baseline or during the follow-up to assess the association between SUA trajectory and all-cause, given other common diseases may have additional effects on all-cause mortality. According to baseline characteristics and previous studies [29, 30], posteriori subgroup analysis stratified by age (<60 or ≥60 years), sex, BMI (<25 or ≥25 kg/m²), and history of hypertension (no or yes) was performed to evaluate whether SUA trajectories exhibit different effect on the outcomes in special populations; interaction between stratified variables and SUA trajectories was tested using likelihood ratio.

All analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). A two-sided \( P < 0.05 \) was considered statistically significant.

**Results**

**Baseline characteristics**

We categorized the study population based on three observed discrete trajectories of SUA during 6-year exposure period (Fig. 2): low-stable (\( n=44,124 \), mean SUA ranged from 236 in 2006 to 249 μmol/L in 2010), moderate-stable (\( n=34,431 \), mean SUA ranged from 324 in 2006 to 354 μmol/L in 2010), and high-stable (\( n=6,984 \), mean SUA from 425 in 2006 to 463 μmol/L in 2010). Baseline characteristics according to SUA trajectory is presented in Table 1. Individuals with a moderate-stable and high-stable trajectories of SUA, compared with individuals with the low-stable group, were more likely to be older; be men, be educated; have a higher percentage of high income; be a current smoker; be a heavy drinker; be of lower percentage of active physical activity; have a higher prevalence of hypertension, dyslipidemia, and metabolic syndrome; take antihypertensive agents and lipid-lowering agents; and have higher levels of FBG, TC, hs-CRP, and SUA and a lower level of eGFR.

**Association between SUA trajectories and outcomes**

During a median follow-up of 6.8 years, we identified 817 (0.96%) incident MI and 6498 (7.60%) all-cause mortality. The association between SUA trajectories and risk of MI and all-cause mortality is presented in Table 2. The incidence rate of MI and all-cause mortality was increased from 1.18 (95% CI, 1.07–1.32) and 9.96 (95% CI, 9.61–10.30) per 1000 person-year in the low-stable trajectory to 2.29 (95% CI, 1.89–2.77) and 16.10 (95% CI, 14.90–17.90) per 1000 person-year in the high-stable trajectory, respectively. The Kaplan–Meier curves also showed that the high-stable trajectory had a higher risk of MI and all-cause mortality than other trajectories (log-rank test, \( P < 0.0001 \), Fig. 3A, B).

Relative to the low-stable trajectory, the high-stable trajectory was associated with 35% higher risk of MI (HR, 1.35; 95% CI, 1.07–1.71) and 22% higher of all-cause mortality (HR, 1.22; 95% CI, 1.12–1.33), after being adjusted for variables in model 3. The results did not materially change by adjusting for average values of continuous covariates during the exposure period, excluding...
MI or mortality cases during the first 2 years of the follow-up (n=2057), or by using competing risk model, or by excluding cardiovascular and cerebrovascular diseases at baseline and the follow-up (n=6030).

Subgroup analysis
The results of subgroup analyses are shown in Fig. 4; there was significant interactions of SUA trajectories with history of hypertension and age in relation to the risk of MI (P for interaction=0.0359) and all-cause mortality (P for interaction=0.0027), respectively. The association high-stable trajectory and the risk of MI was pronounced among individuals without a history of hypertension (HR, 1.90; 95% CI, 1.30–2.79) than those with a history of hypertension (HR, 1.13; 95% CI, 0.84–1.51). Moreover, a stronger relationship between high-stable trajectory and all-cause mortality was found in young adults (aged <60 years) than elders (aged ≥60 years). The association of SUA trajectories with MI and all-cause mortality was consistent across other subgroups (P for interaction >0.05).

Discussion
In this prospective cohort study, we identified 3 heterogeneous SUA trajectories, in which participants shared a similar pattern change in SUA levels during a 6-year exposure period. Participants in the high-stable group had the highest risk of MI and all-cause mortality. The associations remained robust among multiple sensitivity analyses. Posteriori subgroup analyses showed that the significant association of high-stable trajectory with MI and all-cause mortality was only observed for individuals without a history of hypertension and those aged <60 years, respectively.

### Table 1 Baseline characteristics of participants per trajectory of SUA

| Characteristics                          | Overall | Low-stable | Moderate-stable | High-stable | P value |
|-----------------------------------------|---------|------------|----------------|-------------|---------|
| Subjects, n                             | 85,503  | 44,124     | 34,431         | 6948        | <0.0001 |
| Age, years                              | 50±12   | 50±11      | 50±13          | 51±12       | <0.0001 |
| Men, n (%)                              | 66,808  | 29,615 (67.1) | 30,523 (88.6) | 6670 (96.0) | <0.0001 |
| High school or above, n (%)             | 6074 (7.3) | 2457 (5.7) | 2785 (8.3) | 832 (12.2) | <0.0001 |
| Income≥800RMB, n (%)                    | 12,172 (14.6) | 5090 (11.8) | 5642 (16.8) | 1440 (21.2) | <0.0001 |
| Current smoker, n (%)                   | 29,102 (34.8) | 11,301 (26.2) | 14,416 (42.8) | 3385 (49.7) | <0.0001 |
| Alcohol use, n (%)                      | 43,744 (66.3) | 25,787 (75.1) | 15,377 (58.7) | 2580 (47.2) | <0.0001 |
| Active physical activity, n (%)         | 75,978 (91.02) | 39,484 (91.6) | 30,340 (90.3) | 113 (1.6) | <0.0001 |
| Hypertension, n (%)                     | 36,250 (42.4) | 17,421 (39.5) | 15,308 (44.5) | 3521 (50.7) | <0.0001 |
| Diabetes mellitus, n (%)                | 7411 (8.7) | 4420 (10.0) | 4516 (7.4) | 439 (6.3) | <0.0001 |
| Dyslipidemia, n (%)                     | 29,952 (35.0) | 13,180 (29.9) | 13,223 (38.4) | 1427 (20.5) | <0.0001 |
| Metabolic syndrome, n (%)               | 14,717 (17.2) | 6060 (13.6) | 6857 (19.9) | 1854 (26.7) | <0.0001 |
| Antihypertensive agents, n (%)          | 8982 (10.5) | 3039 (6.9) | 4516 (13.1) | 1427 (20.5) | <0.0001 |
| Hypoglycemic agents, n (%)              | 1898 (2.2) | 1047 (2.4) | 709 (2.1) | 142 (2.0) | <0.0001 |
| Lipid-lowering agents, n (%)            | 777 (0.9) | 269 (0.6) | 395 (1.2) | 113 (1.6) | <0.0001 |
| Body mass index, kg/m²                  | 25±3 | 24±3 | 25±3 | 26±3 | <0.0001 |
| Systolic blood pressure, mmHg           | 130±20 | 128±20 | 131±20 | 134±21 | <0.0001 |
| Diastolic blood pressure, mmHg          | 83±11 | 82±11 | 84±11.82 | 86±12 | <0.0001 |
| Fasting blood glucose, mmol/L           | 5.4±1.6 | 5.5±1.7 | 5.3±1.3 | 5.4±1.5 | <0.0001 |
| Total cholesterol, mmol/L               | 4.9±1.1 | 4.8±1.2 | 5.1±1.0 | 5.2±1.1 | <0.0001 |
| eGFR, mL/min/1.73m²                     | 82±25 | 83±23 | 83±27 | 80±25 | <0.0001 |
| hs-CRP, mg/L                            | 2.3±6.2 | 2.0±5.7 | 2.9±6.4 | 3.0±7.2 | <0.0001 |
| SUA                                    | 287±82 | 236±53 | 324±58 | 425±74 | <0.0001 |

Continuous variables were expressed as mean ± standard deviation and were compared with ANOVA, and categorical variables were expressed as frequency with proportion and were compared with chi-square test

Abbreviations: eGFR estimated glomerular filtration rate, hs-CRP high-sensitivity C-reactive protein; SUA, serum uric acid
The association of changes in SUA levels with MI and all-cause mortality risk remains an issue of contention [31–35]. It is worthy to note that SUA changes were measured based on SUA levels at baseline and the end of the follow-up, thereby oversimplifying the heterogeneity and complex patterns of longitudinal SUA changes. In contrast, group-based trajectory is a data-driven approach that can identify distinct clusters of individuals who are following similar trajectories and summarize the trajectory for each group over time in an easily understandable graphical depiction. With this method, our present findings identified three SUA trajectories and demonstrated that high-stable SUA during 6-year exposure period increased the risk of MI and all-cause mortality. These findings suggested that monitoring such distinct SUA trajectories may enhance the identification of at risk individuals.

### Table 2: HRs (95% CIs) for incident myocardial infarction and all-cause mortality per trajectory of SUA trajectories

| SUA trajectory group | Low-stable | Modera-te-stable | High-stable | P for trend |
|----------------------|------------|-----------------|-------------|------------|
| **Myocardial infarction** |            |                 |             |            |
| Cases, n (%)         | 342 (0.78) | 372 (1.08)      | 103 (1.48)  | <0.0001    |
| Incidence rate<sup>a</sup> | 1.18 (1.07–1.32) | 1.66 (1.50–1.84) | 2.29 (1.89–2.77) |            |
| Model 1              | Reference  | 1.41 (1.21–1.63) | 1.94 (1.56–2.42) | <0.0001 |
| Model 2              | Reference  | 1.14 (0.98–1.32) | 1.53 (1.22–1.91) | <0.0001 |
| Model 3              | Reference  | 1.10 (0.95–1.28) | 1.35 (1.07–1.71) | 0.0146 |
| Sensitivity analysis<sup>b</sup> | Reference  | 1.09 (0.93–1.27) | 1.33 (1.05–1.67) | 0.0264 |
| Sensitivity analysis<sup>c</sup> | Reference  | 1.06 (0.88–1.28) | 1.50 (1.14–1.97) | 0.0158 |
| Sensitivity analysis<sup>d</sup> | Reference  | 1.06 (0.91–1.23) | 1.33 (1.06–1.66) | 0.0317 |
| Sensitivity analysis<sup>e</sup> | Reference  | 1.10 (0.94–1.28) | 1.33 (1.05–1.68) | 0.0246 |
| **All-cause mortality** |            |                 |             |            |
| Cases, n (%)         | 2886 (6.54) | 2884 (8.38)    | 728 (10.48) | <0.0001    |
| Incidence rate<sup>f</sup> | 9.96 (9.61–10.30) | 12.80 (12.40–13.30) | 16.10 (14.90–17.30) |            |
| Model 1              | Reference  | 1.29 (1.23–1.36) | 1.63 (1.50–1.76) | <0.0001 |
| Model 2              | Reference  | 1.00 (0.95–1.05) | 1.18 (1.09–1.28) | 0.0040 |
| Model 3              | Reference  | 1.04 (0.98–1.10) | 1.22 (1.12–1.33) | <0.0001 |
| Sensitivity analysis<sup>g</sup> | Reference  | 1.04 (0.99–1.10) | 1.20 (1.10–1.30) | <0.0001 |
| Sensitivity analysis<sup>h</sup> | Reference  | 1.04 (0.98–1.11) | 1.24 (1.12–1.38) | 0.003 |
| Sensitivity analysis<sup>i</sup> | Reference  | 1.02 (0.94–1.05) | 1.15 (1.06–1.26) | 0.0022 |
| Sensitivity analysis<sup>j</sup> | Reference  | 1.03 (0.97–1.10) | 1.21 (1.10–1.34) | 0.0010 |

Model 1: unadjusted
Model 2: adjusted for age, gender, and baseline SUA
Model 3: further adjusted for education, income, smoking status, alcohol use, physical activity, history of hypertension, diabetes and dyslipidemia, antihypertensive agents, hypoglycemic agents, lipid-lowering agents, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, total cholesterol, estimated glomerular filtration rate, and high-sensitivity C-reactive protein

Abbreviations: CI Confidence interval, HR Hazard ratio, SUA Serum uric acid
<sup>a</sup> Incidence rate per 1000 person-years
<sup>b</sup> Sensitivity analysis was adjusted for average body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, estimated glomerular filtration rate, high-sensitivity C-reactive protein, and SUA during the exposure period and other variables at baseline in model 3
<sup>c</sup> Sensitivity analysis excluded incident myocardial infarction or death within the first 2 years of follow-up and adjusted for variables in model 3
<sup>d</sup> Sensitivity analysis was adjusted for metabolic syndrome instead of its components and other variables in model 3
<sup>e</sup> Sensitivity analysis was conducted using Fine-Gray competing risk model considering non-MI deaths as competing risk events and adjusted for variables in model 3
<sup>f</sup> Sensitivity analysis excluded participants with cardiovascular or cerebrovascular disease and adjusted for variables in model 3
<sup>g</sup> Sensitivity analysis excluded participants with cardiovascular or cerebrovascular disease and adjusted for variables in model 3

The posteriori subgroup analysis found that hypertension modified the association between SUA trajectories and MI risk and subjects without hypertension exhibited a high risk of MI, while the relationship seemed insignificant in those with hypertension. This finding was supported by the Rotterdam Study that higher SUA level was significantly associated with MI risk in non-hypertensive subjects, but not in hypertensive subjects [36]. One possible explanation for the moderating effects of baseline hypertension is that the relationship between SUA and future MI risk could be mediated through developing hypertension during follow-up [37]. Therefore, the associations were weakened among participants with
Fig. 3 Kaplan–Meier curves of A myocardial infarction and B all-cause mortality incidence rate by serum uric acid trajectories.

Fig. 4 Subgroup analyses for the association with serum uric acid trajectories with risk of myocardial infarction and all-cause mortality. Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio. Adjusted for age, gender, education, income, smoking status, alcohol use, physical activity, history of hypertension, diabetes and dyslipidemia, antihypertensive agents, hypoglycemic agents, lipid-lowering agents, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, total cholesterol, estimated glomerular filtration rate, high-sensitivity C-reactive protein, and baseline serum uric acid other than variables for stratification.
hypertension at baseline. This suggested that non-hypertensive individuals with high longitudinal SUA pattern warrant more particular vigilance and should be followed up more closely for the existence and development of MI risk.

In regard to all-cause mortality, when stratified by age, the association between SUA trajectories and all-cause mortality was significant among individuals aged <60 years but not in those aged ≥60 years. The reason for the discrepancy may be that young adults were more likely to have unhealthy lifestyle, which leads to levels of SUA increased rapidly which thus may cause organ damage, such as kidney disease [38]. The organ damage in young adults may be an important contributor in mortality among young adults. These finding emphasized the importance of early control of SUA during the life course.

The biological mechanisms underlying the association of SUA trajectories with MI and all-cause mortality mainly included oxidative stress, systematic inflammation, and endothelial dysfunction caused by long-term high SUA levels [39].

Furthermore, SUA trajectories have been reported to be correlated closely with cardiovascular risk factors, such as hypertension [40], diabetes [30], non-alcoholic fatty liver disease [41], and chronic kidney disease [42], which can contribute to the development of MI and reduce the longevity of the affected individuals.

Strengths and limitations
The strengths of the present study include its large sample size, prospective longitudinal design, long follow-up period, repeated measurements of SUA levels, and the applied SUA longitudinal trajectories to estimate the risk of MI and all-cause mortality. However, our study also has several limitations. First, a history of gout and the mediators for hyperuricemia or gout were not recorded in our study. Second, information on fructose-soft drinks was not available in our database, which may significantly increase SUA levels [43, 44]. However, since our study population were mainly middle-age or elderly, the proportion of participants with fructose-soft drinks may be low and thus may not have a substantial influence on the results. Third, we did not collect information on specific causes of death, while we performed sensitivity analyses by excluding those whose deaths were from cardiovascular and cerebrovascular diseases at baseline and during the follow up.

Conclusions
In conclusion, our study found that high-stable SUA trajectories were associated with an increased risk of MI and all-cause mortality. Furthermore, subgroup analysis showed the association of SUA trajectories with MI and all-cause mortality was higher in non-hypertensive subjects and young adults, respectively. These findings suggested that monitoring long-term SUA patterns may contribute additional information for identifying subjects at higher risk of MI and all-cause mortality, and highlight the importance of maintaining normal SUA during the life course.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13075-022-02812-y.

Additional file 1: Table S1. Baseline characteristics of included and excluded participants due to missing data on SUA.

Acknowledgements
We thank all study participants, their relatives, the members of the survey teams at the 11 regional hospitals of the Kailuan Medical Group, and the project development and management teams at the Beijing Tiantan Hospital and the Kailuan Group.

Authors’ contributions
SW, AW, and YL designed the study and interpreted the data. XT drafted the manuscript, performed the statistical analyses, and interpreted the data. YZ and SC revised the manuscript and interpreted the data. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (81773512), National Key Research and Development Program of China (2018YFC1312400 and 2018YFC1312402), Beijing Municipal Administration of Hospitals Incubating Program (PX2020021), Beijing Excellent Talents Training Program (2018000021469G234), and Young Elite Scientists Sponsorship Program by CAST (2018QNRC001).

Availability of data and materials
The data generated by our research could be made available upon request to the corresponding authors.

Declarations

Ethics approval and consent to participate
The study was performed according to the guidelines of the Helsinki Declaration and was approved by the Ethics Committee of Kailuan General Hospital (approval number: 2006-05) and Beijing Tiantan Hospital (approval number: 2010-014-01). All participants provided informed written consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, No.10 Xitoutiao, You’Anmen Wai, Fengtai District, Beijing 100069, China. 2Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China. 3Department of Cardiology, Kailuan Hospital, North China University of Science and Technology, 57 Xinhuab East Rd, Tangshan 063000, China. 4China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing 100070, China. 5Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
1. Hu L, Hu G, Xu B, Zhu L, Zhou W, Wang T, et al. U-shaped association of serum uric acid with all-cause and cause-specific mortality in US adults: a cohort study. J Clin Endocrinol Metab. 2020;105(1):dgz068.

2. Yang X, Gu J, Lv H, Li H, Cheng Y, Liu Y, et al. Uric acid induced inflammatory responses in endothelial cells via up-regulating proinflammatory receptor. Biomed Pharmacother. 2019;109:1163–70.

3. Aroor AR, Jia G, Habibi J, Sun Z, Ramirez-Perez FJ, Brady B, et al. Uric acid promotes vascular stiffness, maladaptive inflammatory responses and proteinuria in western diet fed mice. Metabolism. 2017;74:32–40.

4. Sánchez-Lozada LG, Lanasa MA, Cristóbal-García M, García-Arroyo F, Soto V, Cruz-Robles D, et al. Uric acid induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121(3-4):e71–8.

5. Kuvabara M, Hisatome I, Niwa K, Hara S, Roncal-Jimenez CA, Bjornstad P, et al. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension (Dallas, Tex : 1979). 2018;71(1):78–86.

6. van der Schaft N, Brahimaj A, Wen KX, Franco OH, Dehghan A. The role of serum uric acid in cardiovascular disease and mortality in the elderly: the role of malnourishment. J Am Heart Assoc. 2021;10(7):e0179482.

7. Tedeschi A, Agostoni P, Pezzuto B, Corra U, Scrutinio D, La Gioia R, et al. Uric acid associated with myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein Mortality RISK study (AMORIS). J Intern Med. 2009;266(5):558–70.

8. Li M, Ye ZC, Li CM, Zhao WB, Tang H, Liu X, et al. Low serum uric acid levels increase the risk of all-cause death and cardiovascular death in hemodialysis patients. Renal Failure. 2020;42(1):315–22.

9. Wang R, Song Y, Yan Y, Ding Z. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: a meta-analysis. Atherosclerosis. 2016;254:193–9.

10. Holmes A, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein Mortality Risk Study (AMORIS). J Intern Med. 2009;266(5):558–70.

11. Ong G, Davis WA, Davis TM. Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2010;53(7):1288–94.

12. Zalawadiya SK, Veeravani N, Mallick-Reddy S, Bavishi C, Lunagaria A, Kottam A, et al. Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol. 2015;22(2):suppl:35–45.

13. Li M, Ye ZC, Li CM, Zhao WB, Tang H, Liu X, et al. Low serum uric acid levels increase the risk of all-cause death and cardiovascular death in hemodialysis patients. Renal Failure. 2020;42(1):315–22.

14. Chang CC, Wu CH, Liu K, Chou R, Kuo C, Huang PH, et al. Association between serum uric acid and the incidence of diabetes and type 2 diabetes mellitus: the Rotterdam study. PloS one. 2017;12(6):e0179482.

15. Tseng WC, Chen YT, Ou SM, Shih CJ, Tarng DC. U-shaped association between serum uric acid levels and cardiovascular risk in nonhypertensive and non-diabetic patients. Renal Failure. 2020;42(1):315–22.

16. Pottel H, Delaney P, Schaeffner E, Dubourg L, Eriksen BO, Melsom T, et al. Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C. Nephrol Dial Transplant. 2017;32(3):497–507.

17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52.

18. Jones BLND. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Sociol Methods Res. 2007;35:542–71.

19. Jin C, Chen S, Vaidya A, Wu Y, Wu Z, Hu FB, et al. Longitudinal change in fasting blood glucose and myocardial infarction risk in a population without diabetes. Diabetes Care. 2017;40(11):1565–72.

20. Wang A, Liu X, Su Z, Chen S, Zhang N, Wu S, et al. Two-year changes in proteinuria and the risk of stroke in the Chinese population: a prospective cohort study. J Am Heart Assoc. 2017;6(7):e006271.

21. Wang C, Yuan Y, Zheng M, Pan A, Wang M, Zhao M, et al. Association of age of onset of hypertension with cardiovascular diseases and mortality. J Am Coll Cardiol. 2020;75(23):2921–30.

22. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas A, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90(1):583–612.

23. Ma C, Pavlova M, Li J, Liu Y, Sun Y, Huang Z, et al. Alcohol consumption and probable rapid eye movement sleep behavior disorder. Ann Clin Transl Neurol. 2018;5(10):1176–83.

24. Huang S, Li J, Shearer GC, Lichtenstein AH, Zheng X, Wu Y, et al. Longitudinal study of alcohol consumption and HDL concentrations: a community-based study. Am J Clin Nutr. 2017;105(4):905–12.

25. Zheng D, Yuan X, Ma C, Liu Y, VanEvery H, Sun Y, et al. Alcohol consumption and sleep quality: a community-based study. Public Health Nutr. 2021;24(15):4851–8.

26. Kottam A, et al. Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol. 2015;22(2):suppl:35–45.

27. Palmer T, Neordergaard B, Benn M, Tybjærg-Hansen A, Davey Smith G, Lawlor D, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ (Clinical research ed). 2013;347:f2462.

28. Chang CC, Wu CH, Liu K, Chou R, Kuo C, Huang PH, et al. Association between serum uric acid and cardiovascular risk in nonhypertensive and non-diabetic individuals: The Taiwan I-Lan Longitudinal Aging Study. Sci Rep. 2018;8(1):5234.

29. Chen JT, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;60(2):225–32.

30. Chuang SY, Chen HJ, Yeh WT, Wu CC, Pan WH. Hyperuricemia and increased risk of ischemic heart disease in a large Chinese cohort. Intern J Cardiol. 2012;154(2):231–3.

31. Tseng WC, Chen YT, Du SM, Shih CJ, Tarng DC. U-shaped association between serum uric acid levels with cardiovascular and all-cause mortality in the elderly: the role of malnourishment. J Am Heart Assoc. 2018;7(4):e007523.

32. Haque T, Rahman S, Islam S, Molla NH, Ali N. Assessment of the relationship between serum uric acid and glucose levels in healthy, prediabetic and diabetic individuals. Diabetol Metab Syndr. 2019;11:49.
41. Ma Z, Xu C, Kang X, Zhang S, Li H, Tao L, et al. Changing trajectories of serum uric acid and risk of non-alcoholic fatty liver disease: a prospective cohort study. J Transl Med. 2020;18(1):133.
42. Tsai CW, Chiu HT, Huang HC, Ting IW, Yeh HC, Kuo CC. Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analyses. Nephrol Dial Transplant. 2018;33(2):231–41.
43. Choi JW, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59(1):109–16.
44. Zhang S, Ma Z, Li Q, Liu J, Tao L, Han Y, et al. Dose-response relationship between distinct serum uric acid trajectories and metabolic syndrome risk: a 5-year prospective cohort study. Nutr Metab Cardiovasc Dis. 2021;31(4):1189–99.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.